OrganiGram Holdings
Market Cap
CA$735.6m
Last Updated
2019/10/21 00:39 UTC
Data Sources
Company Financials +
Executive Summary
OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada.
Snowflake
Fundamentals
Solid track record with high growth potential.
Similar Companies
Share Price & News
How has OrganiGram Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
13.0%
OGI
2.6%
CA Pharmaceuticals
-0.2%
CA Market
1 Year Return
-21.4%
OGI
-50.2%
CA Pharmaceuticals
1.5%
CA Market
Return vs Industry: OGI exceeded the Canadian Pharmaceuticals industry which returned -50.2% over the past year.
Return vs Market: OGI underperformed the Canadian Market which returned 1.5% over the past year.
Shareholder returns
| OGI | Industry | Market | |
|---|---|---|---|
| 7 Day | 13.0% | 2.6% | -0.2% |
| 30 Day | -13.6% | -20.3% | -3.5% |
| 90 Day | -41.0% | -32.5% | -1.8% |
| 1 Year | -21.4%-21.4% | -50.2%-50.2% | 5.1%1.5% |
| 3 Year | 64.7%64.7% | 78.2%76.8% | 13.3%3.2% |
| 5 Year | 295.8%295.8% | 285.7%285.7% | 25.2%7.2% |
Price Volatility Vs. Market
How volatile is OrganiGram Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
What Kind Of Investor Owns Most Of OrganiGram Holdings Inc. (CVE:OGI)?6 months ago | Simply Wall St
Can OrganiGram Holdings Inc.'s (CVE:OGI) ROE Continue To Surpass The Industry Average?6 months ago | Simply Wall St
The OrganiGram Holdings (CVE:OGI) Share Price Is Up 1113% And Shareholders Are EuphoricValuation
Is OrganiGram Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OGI (CA$4.71) is trading below our estimate of fair value (CA$20.7)
Significantly Below Fair Value: OGI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OGI is poor value based on its PE Ratio (20.5x) compared to the Pharmaceuticals industry average (11.4x).
PE vs Market: OGI is poor value based on its PE Ratio (20.5x) compared to the Canadian market (13.7x).
Price to Earnings Growth Ratio
PEG Ratio: OGI is good value based on its PEG Ratio (0.6x)
Price to Book Ratio
PB vs Industry: OGI is overvalued based on its PB Ratio (2.2x) compared to the CA Pharmaceuticals industry average (1.9x).
Next Steps
Future Growth
How is OrganiGram Holdings forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
34.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OGI's forecast earnings growth (34.7% per year) is above the savings rate (1.9%).
Earnings vs Market: OGI's earnings (34.7% per year) are forecast to grow faster than the Canadian market (13.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OGI's revenue (31.6% per year) is forecast to grow faster than the Canadian market (5.7% per year).
High Growth Revenue: OGI's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OGI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OrganiGram Holdings performed over the past 5 years?
73.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: OGI has become profitable over the past 5 years, growing earnings by 73.6% per year.
Accelerating Growth: OGI's earnings growth over the past year (1383%) exceeds its 5-year average (73.6% per year).
Earnings vs Industry: OGI earnings growth over the past year (1383%) exceeded the Pharmaceuticals industry 15.6%.
Return on Equity
High ROE: OGI's Return on Equity (9.2%) is considered low.
Return on Assets
ROA vs Industry: OGI has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: OGI has significantly improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is OrganiGram Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: OGI's short term assets (CA$232.5M) exceeds its short term liabilities (CA$25.7M)
Long Term Liabilities: OGI's short term assets (232.5M) exceeds its long term liabilities (65.9M)
Debt to Equity History and Analysis
Debt Level: OGI's debt to equity ratio (14.7%) is considered satisfactory
Reducing Debt: Insufficient data to determine if OGI's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: OGI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: OGI's interest payments on its debt are well covered by EBIT (5x coverage).
Balance Sheet
Inventory Level: OGI has a high level of physical assets or inventory.
Debt Coverage by Assets: OGI's debt is covered by short term assets (assets are 4.699320x debt).
Next Steps
Dividend
What is OrganiGram Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate OGI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OGI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if OGI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OGI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OGI's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of OrganiGram Holdings's salary, the management and board of directors tenure and is there insider trading?
1.8yrs
Average management tenure
CEO
Greg Engel (54yo)
2.6yrs
Tenure
CA$387,957
Compensation
Mr. Greg Engel has been Chief Executive Officer of OrganiGram Holdings Inc. since March 13, 2017. Mr. Engel has served in a number of senior-level and executive positions in related industries over the pas ...
CEO Compensation Analysis
Compensation vs. Market: Greg's total compensation ($USD295.38K) is below average for companies of similar size in the Canadian market ($USD1.08M).
Compensation vs Earnings: Greg's compensation has increased by more than 20% in the past year.
Management Age and Tenure
1.8yrs
Average Tenure
46yo
Average Age
Experienced Management: OGI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Age and Tenure
1.7yrs
Average Tenure
Experienced Board: OGI's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: OGI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 6,495 |
| Max Price | CA$4.68 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,500 |
| Max Price | CA$5.53 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 950 |
| Max Price | CA$6.26 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,740 |
| Max Price | CA$5.99 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,160 |
| Max Price | CA$8.61 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 865 |
| Max Price | CA$8.26 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 6,000 |
| Max Price | CA$7.42 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 83,057 |
| Max Price | CA$7.45 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,100 |
| Max Price | CA$5.59 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 5,620 |
| Max Price | CA$5.84 |
Ownership Breakdown
Management Team
Helen Martin (41yo)
Senior VP of Strategic & Legal Affairs and Company Secretary
- Tenure: 0.5yrs
Paolo De Luca (46yo)
Chief Financial Officer
- Tenure: 1.8yrs
- Compensation: CA$253.15k
Amy Schwalm
Vice President of Investor Relations
- Tenure: 0.8yrs
Jeff Purcell
Vice President - Operations
- Tenure: 2.3yrs
- Compensation: CA$237.81k
Larry Rogers
Vice President of International Business Development
- Tenure: 2yrs
- Compensation: CA$222.73k
Ray Gracewood
Senior Vice President of Marketing & Communications
- Tenure: 0.5yrs
- Compensation: CA$177.11k
Peter Hanson
Director of Finance
- Tenure: 1.8yrs
- Compensation: CA$143.13k
Greg Engel (54yo)
CEO & Director
- Tenure: 2.6yrs
- Compensation: CA$387.96k
Tim Emberg
Senior Vice President of Sales & Commercial Operations
- Tenure: 2yrs
- Compensation: CA$285.35k
James Cavanagh
Chief of Staff
- Tenure: 0.5yrs
Board Members
Peter Amirault
Chairman & Lead Director
- Tenure: 1.6yrs
- Compensation: CA$72.67k
Derrick West
Independent Director
- Tenure: 1.8yrs
- Compensation: CA$41.74k
Dexter D. John (49yo)
Independent Director
- Tenure: 0.8yrs
Michel Bourque
Independent Director
- Tenure: 4.8yrs
- Compensation: CA$56.22k
Sherry Porter
Independent Director
- Tenure: 0.8yrs
Greg Engel (54yo)
CEO & Director
- Tenure: 2.6yrs
- Compensation: CA$387.96k
Company Information
OrganiGram Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OrganiGram Holdings Inc.
- Ticker: OGI
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$735.604m
- Shares outstanding: 156.18m
- Website: https://www.organigram.ca
Number of Employees
Location
- OrganiGram Holdings Inc.
- 35 English Drive
- Moncton
- New Brunswick
- E1E 3X3
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OGI | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Aug 2014 |
| OGI | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Aug 2014 |
| 0OG | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Aug 2014 |
| 0VB6 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Aug 2014 |
Biography
OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-ro ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 00:39 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/05/31 |
| Annual Earnings | 2018/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.